Dopamine Release and Psychosis Outcomes
Author Information
Author(s): Ana Weidenauer, Ulrich Sauerzopf, Martin Bauer, Carina Bum, Cornelia Diendorfer, Irena Dajic, Alina Kastner, Karsten Bamminger, Lukas Nics, Cecile Philippe, Marcus Hacker, Dan Rujescu, Wolfgang Wadsak, Nicole Praschak-Rieder, Matthäus Willeit
Primary Institution: Medical University of Vienna
Hypothesis
Patients responding to antipsychotic treatment will show higher d-amphetamine-induced dopamine release.
Conclusion
Dopamine release is associated with the severity and persistence of symptoms during the first year of psychosis.
Supporting Evidence
- Dopamine release in the ventral striatum was significantly associated with reductions in positive symptoms.
- Dopamine release in the globus pallidus correlated with decreases in negative and general symptoms.
- Higher dopamine release in the substantia nigra predicted larger reductions in general symptoms.
Takeaway
This study looked at how dopamine release affects symptoms in people with first-episode psychosis. It found that more dopamine release is linked to better symptom improvement.
Methodology
Patients underwent PET scans to measure dopamine release before and after d-amphetamine administration, followed by a year of clinical monitoring.
Potential Biases
Potential confounding effects from different types and doses of antipsychotics and other medications prescribed.
Limitations
The small sample size may limit the power to detect small effects, and the naturalistic design means patients received varying treatments.
Participant Demographics
21 antipsychotic-naive patients, 6 female, mean age 25.1 years.
Statistical Information
P-Value
0.04
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website